Vertex Pharmaceuticals (VRTX) Stock Forecast & Price Target

$366.54 -9.09 (-2.42%)

Closing price 08/8/2025 04:00 PM Eastern

Extended Trading

$366.75 +0.21 (+0.06%)

As of 08/8/2025 07:58 PM Eastern

Vertex Pharmaceuticals - Analysts' Recommendations and Stock Price Forecast (2025)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Moderate Buy

Based on 27 Analyst Ratings

Sell
0

Hold
13

Buy
14

Based on 27 Wall Street analysts who have issued ratings for Vertex Pharmaceuticals in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 27 analysts, 13 have given a hold rating, 13 have given a buy rating, and 1 has given a strong buy rating for VRTX.

Consensus Price Target

$497.10
35.62% Upside

According to the 27 analysts' twelve-month price targets for Vertex Pharmaceuticals, the average price target is $497.10. The highest price target for VRTX is $575.00, while the lowest price target for VRTX is $405.00. The average price target represents a forecasted upside of 35.62% from the current price of $366.54.

Get the Latest News and Ratings for VRTX and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Vertex Pharmaceuticals and its competitors.

VRTX Analyst Ratings Over Time

Type	Current Forecast 8/9/24 to 8/9/25	1 Month Ago 7/10/24 to 7/10/25	3 Months Ago 5/11/24 to 5/11/25	1 Year Ago 8/10/23 to 8/9/24
Strong Buy	1 Strong Buy rating(s)	1 Strong Buy rating(s)	1 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	13 Buy rating(s)	13 Buy rating(s)	15 Buy rating(s)	16 Buy rating(s)
Hold	13 Hold rating(s)	14 Hold rating(s)	13 Hold rating(s)	7 Hold rating(s)
Sell	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)	3 Sell rating(s)
Consensus Price Target	$497.10	$511.62	$515.04	$485.91
Forecasted Upside	35.62% Upside	6.69% Upside	21.10% Upside	3.73% Upside
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy	Moderate Buy

VRTX Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

VRTX Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Vertex Pharmaceuticals Stock vs. The Competition

Type	Vertex Pharmaceuticals	Medical Companies	S&P 500
Consensus Rating Score	2.56	2.80	2.53
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy
Predicted Upside	35.62% Upside	27,870.98% Upside	13.84% Upside
News Sentiment Rating	Positive News See Recent VRTX News	Neutral News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst Name	Action	Rating	Price Target	Upside/Downside on Report Date
8/6/2025	Canaccord Genuity Group 2 of 5 stars	Whitney Ijem Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Target	Hold ➝ Hold	$424.00 ➝ $411.00	+6.45%
8/6/2025	Guggenheim 2 of 5 stars	Debjit Chattopadhyay Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Target	Buy ➝ Buy	$558.00 ➝ $546.00	+40.91%
8/6/2025	Wells Fargo & Company 3 of 5 stars	Mohit Bansal Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Equal Weight ➝ Overweight	$460.00	+22.67%
8/5/2025	Scotiabank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Greg Harrison Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Target	Sector Perform ➝ Sector Perform	$442.00 ➝ $438.00	+11.47%
8/5/2025	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Joon Lee Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Target	Buy ➝ Buy	$520.00 ➝ $490.00	+24.70%
8/5/2025	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Brian Abrahams Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Target	Sector Perform ➝ Sector Perform	$430.00 ➝ $405.00	+3.86%
8/5/2025	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Colin Bristow Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Target	Buy ➝ Buy	$582.00 ➝ $553.00	+37.88%
8/5/2025	BMO Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating	Evan Seigerman Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Target	Outperform ➝ Outperform	$557.00 ➝ $530.00	+12.22%
8/5/2025	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Carter Gould Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Target	Overweight ➝ Overweight	$535.00 ➝ $485.00	+2.70%
8/5/2025	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating	Paul Matteis Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Target	Hold ➝ Hold	$494.00 ➝ $455.00	-3.66%
Get the Latest News and Ratings for VRTX and Related Stocks Enter your email address below to receive the latest news and analysts' ratings for Vertex Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.
8/5/2025	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Andrew S. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Target	Buy ➝ Buy	$550.00 ➝ $478.00	+1.21%
8/5/2025	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Matthew Harrison Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Target	Equal Weight ➝ Equal Weight	$460.00 ➝ $439.00	-7.04%
7/14/2025	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Jessica Fye Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Overweight ➝ Overweight	$515.00 ➝ $517.00	+9.43%
5/23/2025	Erste Group Bank Subscribe to MarketBeat All Access for the recommendation accuracy rating	H. Engel Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
5/7/2025	Wolfe Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	A. Chen Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Outperform ➝ Peer Perform
5/6/2025	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Buy ➝ Buy
5/6/2025	Leerink Partnrs Subscribe to MarketBeat All Access for the recommendation accuracy rating	D. Risinger Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
5/6/2025	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Outperform
5/6/2025	Leerink Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating	David Risinger Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Market Perform	$550.00 ➝ $503.00	+0.56%
5/6/2025	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Joseph Stringer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Hold ➝ Hold
3/31/2025	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Ying Huang Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Buy ➝ Buy	$555.00 ➝ $567.00	+15.08%
2/11/2025	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Gena Wang Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Equal Weight ➝ Equal Weight	$435.00 ➝ $467.00	+1.35%
1/27/2025	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Christopher Raymond Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Target	Overweight ➝ Overweight	$535.00 ➝ $533.00	+20.72%
12/19/2024	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating		Downgrade	Outperform ➝ Market Perform
12/9/2024	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Upgrade	Hold ➝ Buy	$500.00 ➝ $550.00	+19.02%
11/14/2024	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Buy	$575.00	+16.25%
10/10/2024	Raymond James Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	D. Brill Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Perform
7/23/2024	TD Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy ➝ Buy	$450.00 ➝ $500.00	+1.60%
6/27/2024	Redburn Atlantic Subscribe to MarketBeat All Access for the recommendation accuracy rating	S. Chesney Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$545.00	+14.98%
6/17/2024	Argus Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy ➝ Buy	$465.00 ➝ $550.00	+15.48%
4/11/2024	Evercore ISI Subscribe to MarketBeat All Access for the recommendation accuracy rating		Upgrade	In-Line ➝ Outperform	$438.00	+10.17%
2/2/2024	Sanford C. Bernstein Subscribe to MarketBeat All Access for the recommendation accuracy rating		Downgrade	Outperform ➝ Market Perform
1/31/2024	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating		Downgrade	Neutral ➝ Underperform	$325.00	-25.27%
1/31/2024	Maxim Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Downgrade	Buy ➝ Hold

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Saturday at 04:05 AM ET.

Should I Buy Vertex Pharmaceuticals Stock? VRTX Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Friday, August 8, 2025. Please send any questions or comments about these Vertex Pharmaceuticals pros and cons to contact@marketbeat.com.

Vertex Pharmaceuticals
Bull Case

Here are some ways that investors could benefit from investing in Vertex Pharmaceuticals Incorporated:

The current stock price is around $385.65, which may present a buying opportunity for investors looking for growth in the biotechnology sector.
Vertex Pharmaceuticals Incorporated reported a strong quarterly earnings result, with earnings per share of $4.52, exceeding analyst expectations, indicating robust financial health.
The company has shown a year-over-year revenue increase of 11.3%, suggesting a positive growth trajectory and strong demand for its products.
Vertex Pharmaceuticals Incorporated has a high net margin of 31.86%, reflecting efficient operations and profitability, which can be attractive to investors seeking stable returns.
With a consensus rating of "Moderate Buy" from analysts, there is a general optimism about the company's future performance, which can encourage investor confidence.

Vertex Pharmaceuticals
Bear Case

Investors should be bearish about investing in Vertex Pharmaceuticals Incorporated for these reasons:

Recent downgrades from several analysts, including a reduction from "outperform" to "peer perform," may indicate concerns about the company's future growth potential.
The stock has experienced fluctuations, with a 1-year high of $519.88 and a low of $372.35, suggesting volatility that could deter risk-averse investors.
Despite strong earnings, the company has a relatively high price-to-earnings (P/E) ratio of 27.57, which may imply that the stock is overvalued compared to its earnings.
Vertex Pharmaceuticals Incorporated's debt-to-equity ratio is very low at 0.01, which, while indicating low debt, may also suggest limited leverage for growth opportunities.
Analysts have set a consensus target price of $497.10, which is significantly higher than the current price, indicating potential market skepticism about achieving that target in the near term.

VRTX Forecast - Frequently Asked Questions

: According to the research reports of 27 Wall Street equities research analysts, the average twelve-month stock price forecast for Vertex Pharmaceuticals is $497.10, with a high forecast of $575.00 and a low forecast of $405.00.
: 27 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Vertex Pharmaceuticals in the last year. There are currently 13 hold ratings, 13 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" VRTX shares.
: According to analysts, Vertex Pharmaceuticals's stock has a predicted upside of 35.62% based on their 12-month stock forecasts.
: Over the previous 90 days, Vertex Pharmaceuticals's stock had 1 upgrade and 1 downgrade by analysts.
: Vertex Pharmaceuticals has been rated by research analysts at BMO Capital Markets, Canaccord Genuity Group, Cantor Fitzgerald, Erste Group Bank, Guggenheim, HC Wainwright, JPMorgan Chase & Co., Morgan Stanley, Royal Bank Of Canada, Scotiabank, Stifel Nicolaus, Truist Financial, UBS Group, and Wells Fargo & Company in the past 90 days.
: Analysts like Vertex Pharmaceuticals less than other "medical" companies. The consensus rating score for Vertex Pharmaceuticals is 2.56 while the average consensus rating score for "medical" companies is 2.80. Learn more on how VRTX compares to other companies.

Stock Forecasts and Research Tools

Related Companies

Today's Ratings

Top-Rated Stocks

More Ratings Tools

This page (NASDAQ:VRTX) was last updated on 8/9/2025 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Vertex Pharmaceuticals (VRTX) Stock Forecast & Price Target